January 22, 2026 GE Aerospace fourth quarter & full year 2025 performance Financial results & company highlights Caution concerning forward-looking statements: This document contains "forward-looking statements" – that is, statements related to future events that by their nature address matters that are, to different degrees, uncertain. For details on the uncertainties that may cause our actual future results to be materially different than those expressed in our forward-looking statements, see www.geaerosp ...

Core Insights - Avantor, Inc. is a global provider of mission-critical products and services in the life sciences and advanced technologies sectors, competing with major players like Thermo Fisher Scientific and Merck KGaA [1] Financial Performance - Avantor's third-quarter 2025 financial results were disappointing, with adjusted earnings per share (EPS) decreasing by 15.4% year-over-year to $0.22, missing the Zacks Consensus Estimate by 4.4% [3][6] - The company reported a GAAP loss per share of $1.04, compared to an EPS of $0.08 in the same quarter last year [3] - Revenues for the quarter totaled $1.62 billion, representing a 5.3% decline from the previous year and falling short of the Zacks Consensus Estimate by 1.6% [4][6] - Organic sales declined by 4.7%, with core segments also posting declines [4][6] Stock Performance and Guidance - Following the disappointing financial performance, Avantor's stock price plunged by 23.2% [5][6] - The company revised its full-year 2025 guidance, projecting EPS to be between $0.88 and $0.92, with organic sales expected to decrease by up to 3.5% [5] - JPMorgan Chase and Co. adjusted the price target for Avantor from $17.00 to $14.00 [5] Insider Activity - On October 30, 2025, SUMME GREGORY L, a director at Avantor, purchased 100,000 shares at $11.25 per share, increasing his total holdings to 300,000 shares [2]